Tumor flare with T-cell-engaging bispecific antibodies

被引：0

作者：

Carlo-Stella, Carmelo ^{[1
,2
]}

Dickinson, Michael J. ^{[3
]}

Iacoboni, Gloria ^{[4
,5
]}

Carpio, Cecilia ^{[4
]}

Dimier, Natalie ^{[6
]}

Weisser, Martin ^{[7
]}

Kwan, Antonia ^{[8
]}

Ferlini, Cristiano ^{[9
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Rozzano, Milano, Italy

[2] IRCCS Humanitas Res Hosp, Dept Oncol & Hematol, Rozzano, Milano, Italy

[3] Royal Melbourne Hosp, PeterMacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Vall dHebron Hosp Univ, Vall dHebron Inst Oncol VHIO, Dept Hematol, Expt Hematol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[5] Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain

[6] Roche Prod Ltd, Welwyn Garden City, England

[7] Roche Innovat Ctr Munich, Roche Pharm Res & Early Dev, Penzberg, Germany

[8] Genentech Inc, Prod Dev Safety, South San Francisco, CA USA

[9] Roche Innovat Ctr New York, Roche Pharm Res & Early Dev, New York, NY USA

来源：

LEUKEMIA & LYMPHOMA | 2024年

关键词：

D O I：

10.1080/10428194.2024.2361100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 50 条

[41] Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Yu, Lin
Huang, Nan
Ge, Liangpeng
Sun, Heng
Fu, Yuna
Liu, Chundong
Wang, Jianhua
[J]. JOURNAL OF BIOLOGICAL ENGINEERING, 2021, 15 (01)
[42] GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Jeong A. Park
Nai-Kong V. Cheung
[J]. Journal of Hematology & Oncology, 13
[43] GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Park, Jeong A.
Cheung, Nai-Kong V.
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[44] Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Lin Yu
Nan Huang
Liangpeng Ge
Heng Sun
Yuna Fu
Chundong Liu
Jianhua Wang
[J]. Journal of Biological Engineering, 15
[45] CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Krupka, Christina
Kufer, Peter
Kischel, Roman
Zugmaier, Gerhard
Boegeholz, Jan
Koehnke, Thomas
Lichtenegger, Felix S.
Schneider, Stephanie
Metzeler, Klaus H.
Fiegl, Michael
Spiekermann, Karsten
Baeuerle, Patrick A.
Hiddemann, Wolfgang
Riethmueller, Gert
Subklewe, Marion
[J]. BLOOD, 2014, 123 (03) : 356 - 365
[46] Incorporation of a repeated polypeptide sequence in therapeutic antibodies as a universal masking procedure: A case study of T cell-engaging bispecific antibodies
Maejima, Atsushi
Suzuki, Saori
Makabe, Koki
Kumagai, Izumi
Asano, Ryutaro
[J]. NEW BIOTECHNOLOGY, 2023, 77 : 80 - 89
[47] Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque
Kamperschroer, Cris
Guffroy, Magali
Shen, Amy
Dokmanovich, Melba
Stubbs, Makeida
O'Donnell, Lynn M.
[J]. JOURNAL OF IMMUNOTHERAPY, 2024, 47 (05) : 160 - 171
[48] T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targeting human breast cancer
Iizuka, Akira
Ashizawa, Tadashi
Ohshima, Keiichi
Kusuhara, Masatoshi
Yamaguchi, Ken
Akiyama, Yasuto
[J]. CANCER SCIENCE, 2018, 109 : 413 - 413
[49] T-cell surface generation of dual bivalent, bispecific T-cell engaging, RNA duplex cross-linked antibodies (dbBiTERs) for re-directed tumor cell lysis
Kujawski, Maciej
Li, Lin
Li, Harry
Yazaki, Paul J.
Swiderski, Piotr
Shively, John E.
[J]. BIOTECHNOLOGY JOURNAL, 2022, 17 (02)
[50] SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents
Madduri, Deepu
Dhodapkar, Madhav, V
Lonial, Saar
Jagannath, Sunday
Cho, Hearn Jay
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 537 - 544

← 1 2 3 4 5 →